These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020. Liang X; Yang Q; Wu P; He C; Yin L; Xu F; Yin Z; Yue G; Zou Y; Li L; Song X; Lv C; Zhang W; Jing B Bioorg Chem; 2021 Aug; 113():105011. PubMed ID: 34091289 [TBL] [Abstract][Full Text] [Related]
3. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315 [TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Hojjat-Farsangi M Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867 [TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinases as targets in cancer therapy - successes and failures. Traxler P Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099 [TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. Ruiz-Camps I; Aguilar-Company J Infect Dis Clin North Am; 2020 Jun; 34(2):257-270. PubMed ID: 32334988 [TBL] [Abstract][Full Text] [Related]
7. Companion biomarkers: paving the pathway to personalized treatment for cancer. Duffy MJ; Crown J Clin Chem; 2013 Oct; 59(10):1447-56. PubMed ID: 23656699 [TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy for advanced breast cancer. Rugo HS Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449 [TBL] [Abstract][Full Text] [Related]
9. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer. Ohno S Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773 [TBL] [Abstract][Full Text] [Related]
10. Targeting the human kinome for cancer therapy. Daly RJ Crit Rev Oncog; 2012; 17(1):vi-vii. PubMed ID: 22471667 [No Abstract] [Full Text] [Related]
11. [Ocular side effects of modern oncological therapy : Immunological checkpoint and MEK/BRAF signal transduction inhibitors]. Thurau S; Wildner G; Gamulescu MA Ophthalmologie; 2023 May; 120(5):559-573. PubMed ID: 37160621 [TBL] [Abstract][Full Text] [Related]
12. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Fortes BH; Liou H; Dalvin LA Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124 [TBL] [Abstract][Full Text] [Related]
13. Precision Management of Advanced Non-Small Cell Lung Cancer. Yang CY; Yang JC; Yang PC Annu Rev Med; 2020 Jan; 71():117-136. PubMed ID: 31986082 [TBL] [Abstract][Full Text] [Related]